Extended Safety and Effectiveness of Tralokinumab in Individuals with Moderate-to-Severe Atopic Dermatitis Over a 6-Year Period: Final Outcomes from the ECZTEND Open-Label Extension Study - Scorecard - MDSpire

Extended Safety and Effectiveness of Tralokinumab in Individuals with Moderate-to-Severe Atopic Dermatitis Over a 6-Year Period: Final Outcomes from the ECZTEND Open-Label Extension Study

  • By

  • Andrew Blauvelt

  • H. Chih-Ho Hong

  • Norito Katoh

  • Richard G. Langley

  • Vivian Laquer

  • Aleksandra Lesiak

  • Ketty Peris

  • Julien Seneschal

  • Juan-Francisco Silvestre

  • Richard B. Warren

  • Andreas Wollenberg

  • Matthew Zirwas

  • Niels Højsager Bennike

  • Farzaneh Safavimanesh

  • Ann-Marie Tindberg

  • Kristian Reich

  • February 5, 2026

  • 0 min

Share

Clinical Scorecard: Extended Safety and Effectiveness of Tralokinumab in Individuals with Moderate-to-Severe Atopic Dermatitis Over a 6-Year Period: Final Outcomes from the ECZTEND Open-Label Extension Study

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients aged ≥ 12 years with moderate-to-severe atopic dermatitis.
Care Setting

Key Highlights

  • Tralokinumab treatment maintained disease control for up to 6 years, with X% of patients achieving IGA 0/1.
  • Long-term safety profile consistent with known data; no new safety signals identified.
  • Favorable benefit-to-risk profile supports long-term use.

Guideline-Based Recommendations

Diagnosis

    Management

    • Consider tralokinumab for patients with moderate-to-severe atopic dermatitis, following specific treatment protocols.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Tralokinumab administered at 300 mg every other week, with optional topical corticosteroids as adjunct therapy.

        Clinical Best Practices

        • Ensure informed consent and adherence to ethical guidelines in clinical trials.
        • Utilize a structured follow-up schedule (e.g., every 3 months) to monitor patient outcomes.

        References

        Original Source(s)

        Extended Safety and Effectiveness of Tralokinumab in Individuals with Moderate-to-Severe Atopic Dermatitis Over a 6-Year Period: Final Outcomes from the ECZTEND Open-Label Extension Study

        • by Andrew Blauvelt, H. Chih-Ho Hong, Norito Katoh, Richard G. Langley, Vivian Laquer, Aleksandra Lesiak, Ketty Peris, Julien Seneschal, Juan-Francisco Silvestre, Richard B. Warren, Andreas Wollenberg, Matthew Zirwas, Niels Højsager Bennike, Farzaneh Safavimanesh, Ann-Marie Tindberg, Kristian Reich

        • February 5, 2026

        Related Content

        Summary of Research: Immunogenicity of Dupilumab in Adult and Pediatric Patients with Atopic Dermatitis

        What Causes the Itch in Dermatitis?

        Scientists discover the mechanism that drives inflammation and itching in the chronic skin condition

        • February 3, 2026

        • 2 min
        Gene Test Guides Eczema Care

        Skin scraping assay may help labs support targeted systemic treatment in atopic dermatitis

        • March 2, 2026

        • 3 min